Anti-PD-1/PD-L1
Phase 2Small molecule
Anti-PD-1/PD-L1 is one of 60 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.
2
Indications
4
Total Trials
2
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
265 competitors in Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisPreclinical
Viread
GileadPreclinical
Sovaldi
GileadPreclinical
Anti-PD-1/PD-L1
SShanghai Zhongshan Hospital
Phase 2
Vermox
WWim Janssens
Preclinical
Doptelet
AAkarx
Preclinical
Miraclid
TTechpool Bio-Pharma Co., Ltd.
Preclinical
Valemetostat
Bristol-Myers SquibbPreclinical
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Alcohol
AstellasPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma1 trial
Advanced/Metastatic Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anti-PD-1/PD-L1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SShanghai Zhongshan Hospital